CompareMedsRx adds Galleri cancer screening access

CompareMedsRx says it is expanding beyond prescription savings by giving users direct access to GRAIL’s Galleri multi-cancer early detection test. The move broadens the platform’s health offerings as it grows from a price-comparison tool into a broader consumer health service.

Why it matters: - CompareMedsRx is moving beyond prescription discounts into earlier disease detection and broader health access. - The addition gives users a new way to pursue proactive cancer screening through a platform they already use for medication savings. - The expansion reflects growing consumer demand for health tools that are easier to find, compare and use.

What happened: - CompareMedsRx announced it will offer direct access to GRAIL’s Galleri multi-cancer early detection test. - The company launched the offering in Schaumburg, Illinois, on Sept. 2, 2026. - Founder and CEO Hiten Gardi said the partnership with GRAIL extends CompareMedsRx’s mission to make healthcare more accessible and transparent. - Users can access the test through comparemedsrx.com/grail-multi-cancer-test.

The details: - CompareMedsRx launched in 2024. - The platform says it now serves more than 250,000 users across 42 active partner organizations. - CompareMedsRx aggregates prices from 24 discount programs across more than 70,000 pharmacies nationwide. - The company says users can save up to 85% on prescription medications. - Galleri is a blood test designed to screen for a cancer signal before symptoms appear. - The test is designed to detect signals for more than 50 types of cancer. - Important safety information says Galleri should be used in addition to healthcare provider-recommended screening tests. - The safety notice says Galleri does not detect a signal for all cancers, and not all cancers can be detected in the blood. - The safety notice says false positive and negative results can occur. - The test is Rx only. - Full safety information is available at full safety information.

Between the lines: - CompareMedsRx is positioning itself as more than a savings platform and more like a broader access point for preventive health services. - The Galleri offering adds a high-profile screening product, which may help the company deepen engagement with users and partners. - The safety language is important because the test is not a replacement for standard screening and has limits like any diagnostic tool.

What's next: - CompareMedsRx will likely use the new offering to continue expanding its health-services lineup. - Users interested in the test can review the product details and safety information before deciding whether to access it through the platform. - The company’s broader growth suggests more non-prescription health offerings could follow.

The bottom line: - CompareMedsRx is broadening its footprint from drug-price comparison into preventive health, with Galleri now available through its platform.